PL396415A1 - Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA - Google Patents

Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA

Info

Publication number
PL396415A1
PL396415A1 PL396415A PL39641511A PL396415A1 PL 396415 A1 PL396415 A1 PL 396415A1 PL 396415 A PL396415 A PL 396415A PL 39641511 A PL39641511 A PL 39641511A PL 396415 A1 PL396415 A1 PL 396415A1
Authority
PL
Poland
Prior art keywords
dna vaccine
protein
inducing
immune response
influenza virus
Prior art date
Application number
PL396415A
Other languages
English (en)
Other versions
PL220281B1 (pl
Inventor
Agnieszka Sirko
Anna Góra-Sochacka
Włodzimierz Zagórski-Ostoja
Anna Stachyra
Róża Sawicka
Bogusław Szewczyk
Beata Gromadzka
Violetta Sączyńska
Katarzyna Florys
Marek Bednarczyk
Paweł Łakota
Zenon Minta
Krzysztof Śmietanka
Original Assignee
Instytut Biochemii I Biofizyki, Polska Akademia Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki, Polska Akademia Nauk filed Critical Instytut Biochemii I Biofizyki, Polska Akademia Nauk
Priority to PL396415A priority Critical patent/PL220281B1/pl
Priority to US14/346,664 priority patent/US9505806B2/en
Priority to PCT/PL2012/000095 priority patent/WO2013043067A2/en
Publication of PL396415A1 publication Critical patent/PL396415A1/pl
Publication of PL220281B1 publication Critical patent/PL220281B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem wynalazku jest szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA. W rozwiazaniu wedlug wynalazku stosuje sie jedno- lub dwukrotna immunizacje kur szczepionka DNA zawierajaca cDNA kodujace zmodyfikowane bialko H5 tj. z delecja miejsca ciecia pomiedzy podjednostkami (zapewnia to wieksze bezpieczenstwo szczepionki). Ponadto, proponowane jest zastosowanie zmienionego regionu kodujacego w taki sposób, aby zapewnic maksymalna wydajnosc produkcji bialka w komórkach ptaków.
PL396415A 2011-09-23 2011-09-23 Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA PL220281B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL396415A PL220281B1 (pl) 2011-09-23 2011-09-23 Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
US14/346,664 US9505806B2 (en) 2011-09-23 2012-09-21 DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine
PCT/PL2012/000095 WO2013043067A2 (en) 2011-09-23 2012-09-21 Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL396415A PL220281B1 (pl) 2011-09-23 2011-09-23 Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA

Publications (2)

Publication Number Publication Date
PL396415A1 true PL396415A1 (pl) 2013-04-02
PL220281B1 PL220281B1 (pl) 2015-09-30

Family

ID=47915058

Family Applications (1)

Application Number Title Priority Date Filing Date
PL396415A PL220281B1 (pl) 2011-09-23 2011-09-23 Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA

Country Status (3)

Country Link
US (1) US9505806B2 (pl)
PL (1) PL220281B1 (pl)
WO (1) WO2013043067A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130031A1 (en) 2015-02-10 2016-08-18 Instytut Biochemii I Biofizyki Pan Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
ES2951259T3 (es) 2011-09-30 2023-10-19 Medicago Inc Aumento del rendimiento de las partículas similares a virus en las plantas
IL241692B2 (en) * 2013-03-28 2023-12-01 Medicago Inc Production of influenza virus-like particles in plants
PL238555B1 (pl) * 2013-12-20 2021-09-06 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5
CN105980561B (zh) 2014-01-10 2020-06-02 莫迪卡戈公司 Cpmv增强子元件
JP6599354B2 (ja) 2014-03-27 2019-10-30 メディカゴ インコーポレイテッド 改変されたｃｐｍｖエンハンサーエレメント
PL235555B1 (pl) * 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2006104615A2 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CA2657849A1 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP3040082A1 (en) 2007-05-31 2016-07-06 Statens Serum Institut Influenza vaccines
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
EP2284260A4 (en) 2008-03-28 2011-08-10 Univ Hokkaido Nat Univ Corp MONOCLONAL ANTIBODY TO HEMAGGLUTININE OF INFLUENZA A VIRUS SUBTYPE H5
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130031A1 (en) 2015-02-10 2016-08-18 Instytut Biochemii I Biofizyki Pan Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Also Published As

Publication number Publication date
WO2013043067A2 (en) 2013-03-28
US20140255343A1 (en) 2014-09-11
PL220281B1 (pl) 2015-09-30
US9505806B2 (en) 2016-11-29
WO2013043067A3 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
PL396415A1 (pl) Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciala specyficznie rozpoznajace bialko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
BR112018012962A2 (pt) vacinas de zika recombinantes
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
UY36006A (es) Construcciones de proteína uspa2 y usos de las mismas.
CO2017007105A2 (es) Nuevos virus de tilapia
BR112014018884A2 (pt) antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
AR079767A1 (es) Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
PH12017500003B1 (en) Vaccine composition for classical swine fever from plant and manufacturing method thereof
BR112017005744A2 (pt) sistema de genética reversa para vírus pichinde e método de uso
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EA201690115A1 (ru) Комбинированные иммуногенные композиции
MX363149B (es) Vacunas de nucleoproteina de la influenza.
PE20180463A1 (es) Virus de la enteritis del pato y usos del mismo
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue